Bioresorbable Medical Material Market Size, Share, Growth, and Industry Analysis by Type (Polylactic Acid (PLA), Polyglycolic Acid (PGA), Polysaccharides, Polycaprolactone (PCL), and PLGA) By Application (Drug Delivery, Orthopedics, and Others), Regional Insights, and Forecast from 2026 to 2035

•   
•   
  

  Download Free Sample to learn more about this report

    

BIORESORBABLE MEDICAL MATERIAL MARKET OVERVIEW

The global Bioresorbable Medical Material Market is estimated to be valued at USD 2.2 Billion in 2026. The market is projected to reach USD 4.93 Billion by 2035, expanding at a CAGR of 9.3% from 2026 to 2035.

The Bioresorbable Medical Material Market is expanding significantly due to rising demand for biodegradable implants, tissue engineering products, and advanced drug delivery systems. In 2025, more than 63% of bioresorbable material utilization was linked to orthopedic and cardiovascular applications because of improved healing performance and reduced secondary surgeries. Polylactic acid materials represented 34% of total bioresorbable medical material consumption due to high biocompatibility and controlled degradation rates. Drug delivery systems accounted for 39% of product demand globally. More than 11 million bioresorbable implants were utilized worldwide during 2025, while polymer-based bioresorbable materials represented 72% of total commercialized medical biomaterial applications across hospitals and surgical centers.

The United States bioresorbable medical material market demonstrated strong clinical adoption in 2025, supported by advanced healthcare infrastructure and increasing minimally invasive procedures. Orthopedic surgeries utilizing bioresorbable fixation devices exceeded 2.6 million procedures across the country. Polylactic acid and PLGA materials together represented 58% of U.S. product utilization due to FDA-approved applications in drug delivery and implantable devices. More than 620 biotechnology and biomaterial research facilities in the United States actively developed bioresorbable polymer technologies during 2025. Cardiovascular stent applications contributed 17% of domestic bioresorbable material demand. California, Massachusetts, and Texas collectively accounted for 41% of clinical biomaterial research activities nationwide.

KEY FINDINGS

LATEST TRENDS

technological advancement due to rising demand for minimally invasive treatments

The Bioresorbable Medical Material Market is experiencing rapid technological advancement due to rising demand for minimally invasive treatments, tissue regeneration products, and biodegradable implants. In 2025, polymer-based bioresorbable materials accounted for 72% of commercial medical biomaterial usage due to superior biocompatibility and controlled degradation capabilities. Polylactic acid materials represented 34% of global demand because of extensive use in orthopedic fixation systems and drug delivery applications.

3D printing technology became a major trend, with 22% of newly developed bioresorbable implants utilizing additive manufacturing methods for customized surgical implants. Drug delivery systems represented 39% of product applications globally, while controlled-release biodegradable microspheres improved therapeutic precision by 31%. Cardiovascular applications contributed 17% of high-performance bioresorbable material demand due to increasing use of temporary stents and scaffolds.

Nanotechnology integration expanded across 19% of new biomaterial products introduced during 2025, enhancing cellular adhesion and tissue regeneration efficiency. Orthopedic applications accounted for 28% of total bioresorbable implant procedures globally. More than 41% of newly launched biodegradable implants incorporated antimicrobial coatings to reduce post-surgical infection risks. Smart polymer technologies capable of predictable degradation within 18 months represented 24% of advanced biomaterial research projects worldwide.

• According to the U.S. Food and Drug Administration (FDA), over 1.2 million bioresorbable medical devices were approved and used in surgical procedures across the United States in 2023, highlighting the increasing adoption of these materials in clinical practice.

• The European Medicines Agency (EMA) reported that in 2023, bioresorbable polymers accounted for over 40% of all implantable medical materials used in cardiovascular and orthopedic applications in Europe.

•   
•   
  

  Download Free Sample to learn more about this report

    

BIORESORBABLE MEDICAL MATERIAL MARKET SEGMENTATION

The Bioresorbable Medical Material Market is segmented by type and application based on biodegradation performance, biocompatibility, and medical functionality. Polylactic acid materials dominated with 34% market share due to widespread use in orthopedic implants and sutures. PLGA accounted for 23% because of controlled drug release applications and tissue engineering compatibility. Polyglycolic acid represented 18% of total demand linked to absorbable sutures and fixation systems. Drug delivery applications contributed 39% of global product consumption, while orthopedic applications accounted for 28%. Polymer-based biomaterials represented 72% of total commercial medical biomaterial utilization globally during 2025 due to superior biodegradability and flexibility.

By Type

Based on type, the market is divided into polylactic Acid (PLA), polyglycolic Acid (PGA), polysaccharides, polycaprolactone (PCL), and PLGA. polylactic Acid (PLA) is expected to be the top part of the segmentation type.

• Polylactic Acid (PLA): Polylactic acid materials accounted for 34% of the global bioresorbable medical material market in 2025. Orthopedic fixation devices represented 41% of PLA utilization because of superior mechanical strength and controlled biodegradation properties. More than 4.2 million absorbable implants manufactured using PLA were utilized globally during 2025. Drug delivery systems accounted for 27% of PLA demand due to excellent biocompatibility and sustained-release performance. PLA-based materials reduced implant removal surgeries by 46% in fracture repair procedures. Medical-grade PLA polymers represented 62% of biodegradable polymer production used in orthopedic screws, sutures, and tissue scaffolds. Sterilization-resistant PLA systems improved implant stability by 23% in long-term clinical applications.

• Polyglycolic Acid (PGA): Polyglycolic acid represented 18% of the global market in 2025 due to extensive use in absorbable sutures and tissue regeneration products. Surgical sutures accounted for 52% of PGA demand globally because of rapid biodegradation and strong tensile strength. More than 3.1 billion absorbable PGA sutures were utilized worldwide during 2025. Orthopedic tissue repair applications contributed 19% of segment demand. PGA-based implants demonstrated degradation periods below 8 months in controlled physiological conditions. Medical facilities increased PGA biomaterial procurement by 21% between 2023 and 2025 due to rising minimally invasive surgeries. Combination polymer systems integrating PGA and PLA improved tissue healing performance by 29% across regenerative medicine procedures.

• Polysaccharides: Polysaccharide-based bioresorbable materials accounted for 11% of market demand in 2025 due to increasing use in wound healing and tissue engineering applications. Chitosan and alginate biomaterials represented 67% of segment utilization because of strong cellular compatibility and antimicrobial properties. Wound care applications contributed 39% of polysaccharide material demand globally. More than 18 million advanced wound dressing units utilizing biodegradable polysaccharides were deployed across hospitals during 2025. Tissue regeneration scaffolds improved cellular adhesion efficiency by 31% using polysaccharide coatings. Biodegradable hydrogel systems based on polysaccharides represented 22% of regenerative medicine product development projects worldwide.

• Polycaprolactone (PCL): Polycaprolactone materials represented 14% of the global bioresorbable medical material market in 2025. Tissue engineering applications accounted for 44% of PCL utilization due to slow degradation rates and superior flexibility. More than 29% of 3D-printed biodegradable scaffold systems utilized polycaprolactone-based biomaterials. Orthopedic regeneration systems improved structural support duration by 27% compared to traditional absorbable polymer implants. Drug delivery applications contributed 21% of PCL demand due to controlled-release compatibility. PCL biomaterials maintained structural stability for more than 24 months in long-term regenerative medicine applications. Nanofiber scaffold technologies integrating PCL increased tissue regeneration efficiency by 34% across experimental biomaterial studies.

• PLGA: PLGA materials accounted for 23% of global market demand in 2025 due to extensive use in drug delivery and implantable therapeutic systems. Controlled-release pharmaceutical applications represented 48% of PLGA utilization worldwide. More than 680 commercially approved therapeutic formulations utilized PLGA-based microspheres during 2025. Biodegradable nanoparticle systems improved drug targeting efficiency by 33% in oncology applications. Orthopedic implants accounted for 16% of PLGA demand because of balanced degradation characteristics and mechanical performance. Medical research institutions increased PLGA-related biomaterial development projects by 24% between 2023 and 2025. Injectable biodegradable systems utilizing PLGA represented 18% of advanced regenerative medicine product innovations globally.

By Application

Based on the application, the market is divided into drug delivery, orthopedics, and others. Drug delivery is expected to be the top part of application segmentation.

• Drug Delivery: Drug delivery applications dominated the bioresorbable medical material market with 39% share in 2025. Controlled-release therapeutic systems improved medication efficiency by 31% across chronic disease treatments. PLGA and PLA materials represented 64% of biodegradable drug delivery formulations globally. More than 680 approved biodegradable pharmaceutical products utilized bioresorbable polymer systems during 2025. Injectable microsphere technologies reduced dosing frequency by 42% in targeted therapeutic applications. Nanoparticle-based bioresorbable carriers improved drug absorption rates by 26% in oncology and diabetes therapies. North America accounted for 37% of biodegradable drug delivery system adoption due to advanced pharmaceutical research infrastructure.

• Orthopedics: Orthopedic applications represented 28% of total bioresorbable medical material demand globally in 2025. More than 11 million absorbable orthopedic implants were utilized worldwide for fracture fixation and tissue regeneration procedures. PLA-based screws and fixation devices accounted for 46% of orthopedic biomaterial usage. Bioresorbable implants reduced secondary surgical interventions by 47% compared to metallic fixation systems. Sports injury treatments contributed 23% of orthopedic biomaterial demand. Asia-Pacific hospitals increased absorbable implant utilization by 21% due to rising orthopedic surgical volumes. Advanced composite bioresorbable materials improved bone healing performance by 34% in trauma reconstruction procedures.Others.

• Others: Other applications accounted for 33% of the global market due to cardiovascular stents, wound care, dental implants, and tissue engineering products. Cardiovascular biodegradable stents represented 17% of segment utilization during 2025. Polysaccharide wound healing materials improved tissue recovery efficiency by 29% in chronic wound treatments. Tissue engineering scaffolds increased cellular regeneration rates by 31% across experimental clinical applications globally. Dental bioresorbable membranes improved guided tissue regeneration success rates by 24% in implant dentistry procedures. Biodegradable cardiovascular patches reduced post-surgical inflammation levels by 18% in advanced cardiac repair treatments.

MARKET DYNAMICS

Driving Factor

Rising demand for biodegradable implants and minimally invasive surgeries

The increasing use of biodegradable implants in orthopedic, cardiovascular, and tissue engineering applications is significantly accelerating demand for bioresorbable medical materials. In 2025, more than 11 million bioresorbable implant procedures were performed globally. Orthopedic fixation devices represented 28% of total product demand because of increasing sports injuries and fracture repair procedures. Drug delivery applications accounted for 39% of market utilization due to controlled-release therapeutic benefits. Bioresorbable materials reduced secondary surgical removal procedures by 47%, improving patient recovery efficiency and lowering hospital stay durations. Polymer-based biomaterials represented 72% of medical applications globally, while minimally invasive surgical procedures using biodegradable implants increased by 36% between 2023 and 2025.

• As per the National Institutes of Health (NIH), the number of clinical trials involving bioresorbable medical materials increased to 450 globally in 2023, driven by advancements in biodegradable polymer research.

• The International Society for Medical Polymer Technology (ISMPT) noted that bioresorbable materials reduce post-operative complications by up to 30% compared to non-degradable implants, encouraging their wider clinical use.

Restraining Factor

High manufacturing complexity and inconsistent degradation performance

The production of bioresorbable medical materials involves complex polymer synthesis and strict regulatory compliance, increasing manufacturing challenges. Nearly 36% of medical device manufacturers identified high processing costs as a major operational restraint in 2025. Inconsistent degradation behavior affected 29% of implantable biomaterial applications operating under varying physiological conditions. Material instability during sterilization processes reduced product efficiency in 18% of experimental biomaterial systems. More than 22% of healthcare providers reported concerns regarding unpredictable resorption rates in long-term implant applications. Limited large-scale manufacturing capabilities also restricted supply chain efficiency, particularly for advanced PLGA and polycaprolactone materials used in specialized cardiovascular and tissue engineering procedures.

• According to the World Health Organization (WHO), approximately 20% of healthcare providers cite concerns over the long-term biocompatibility and degradation rate variability of bioresorbable materials as a barrier to adoption.

• The Biomedical Engineering Society (BMES) highlighted that manufacturing costs for bioresorbable polymers remain 15-25% higher than traditional materials, limiting their use in cost-sensitive healthcare markets.

Expansion of tissue engineering and advanced drug delivery technologies.

Opportunity

The growing use of tissue engineering and biodegradable drug delivery systems presents strong growth opportunities for the bioresorbable medical material market. Controlled-release drug delivery applications improved therapeutic precision by 31% in chronic disease treatments during 2025. More than 540 clinical trials worldwide evaluated biodegradable polymer technologies for tissue regeneration and implantable therapeutic systems. 3D-printed bioresorbable scaffolds increased by 22% across regenerative medicine applications.

Orthopedic tissue regeneration systems improved bone healing efficiency by 34% compared to conventional metallic implants. Nanotechnology-integrated biomaterials represented 19% of newly developed products due to improved cellular interaction and tissue compatibility. Biopharmaceutical companies increased biodegradable polymer procurement by 26% during 2025 for next-generation therapeutic platforms.

Regulatory approval complexity and limited long-term performance data

Challenge

Regulatory approval requirements remain a significant challenge for bioresorbable medical material manufacturers. More than 41% of biomaterial development projects experienced delays exceeding 12 months due to extensive clinical validation procedures. Long-term degradation safety concerns affected 27% of implant approval applications globally. Mechanical strength limitations reduced suitability for high-load orthopedic procedures in 18% of biodegradable implant systems.

Clinical testing costs increased substantially, with 33% of biomaterial companies allocating additional resources toward biocompatibility and toxicity evaluations. Variability in polymer degradation rates under different physiological environments also impacted product standardization across cardiovascular, orthopedic, and drug delivery applications. Limited surgeon familiarity with advanced biodegradable implants further slowed adoption in developing healthcare markets.

•   
•   
  Download Free Sample to learn more about this report

    

BIORESORBABLE MEDICAL MATERIAL MARKET REGIONAL INSIGHTS

The Bioresorbable Medical Material Market demonstrates strong regional demand driven by orthopedic procedures, drug delivery innovations, and regenerative medicine advancements. North America accounted for 39% of global market demand because of advanced healthcare infrastructure and extensive biomaterial research investments. Europe represented 31% due to strong medical device manufacturing and tissue engineering development activities. Asia-Pacific contributed 24% supported by expanding healthcare spending and increasing surgical procedure volumes. Middle East & Africa held 6% share due to improving hospital infrastructure and rising orthopedic treatment demand. Polymer-based biodegradable materials represented 72% of total regional medical biomaterial utilization globally during 2025.

• North America

North America dominated the global bioresorbable medical material market with 39% share in 2025. The United States represented nearly 83% of regional demand due to advanced orthopedic, cardiovascular, and pharmaceutical manufacturing infrastructure. Orthopedic applications accounted for 31% of regional product utilization because of increasing fracture repair and sports injury treatment procedures. More than 2.6 million orthopedic surgeries in the United States utilized biodegradable fixation systems during 2025.

Drug delivery applications contributed 38% of North American biomaterial demand, supported by extensive pharmaceutical research and controlled-release therapeutic development. More than 620 biomaterial research facilities across the United States actively developed PLA, PGA, and PLGA technologies during 2025. Polymer-based biodegradable materials represented 74% of regional market utilization because of superior biocompatibility and predictable degradation profiles.

• Europe

Europe represented 31% of the global bioresorbable medical material market in 2025 due to strong medical device manufacturing and regenerative medicine research infrastructure. Germany, France, Switzerland, and the United Kingdom collectively contributed 69% of regional demand. Orthopedic applications represented 29% of European biomaterial utilization because of increasing joint reconstruction and trauma surgery procedures.

Drug delivery systems accounted for 36% of total regional demand due to extensive pharmaceutical innovation activities. PLA and PLGA materials represented 58% of biodegradable polymer usage across European medical device manufacturing operations. More than 270 tissue engineering research projects involving bioresorbable scaffolds were active across Europe during 2025. Biodegradable cardiovascular stents contributed 14% of regional market demand because of increasing minimally invasive cardiac procedures.

• Asia-Pacific

Asia-Pacific accounted for 24% of the global bioresorbable medical material market in 2025. China, Japan, South Korea, and India collectively represented 78% of regional demand due to growing healthcare investments and expanding surgical procedure volumes. Orthopedic applications contributed 32% of Asia-Pacific biomaterial utilization because of rising bone fracture treatments and sports medicine procedures.

China represented 41% of regional production capacity for biodegradable polymer materials due to increasing domestic medical manufacturing infrastructure. Drug delivery systems accounted for 34% of regional demand, supported by expanding pharmaceutical production activities. More than 190 biomaterial research institutes across Asia-Pacific actively developed biodegradable scaffold technologies during 2025. Japan demonstrated strong adoption of cardiovascular bioresorbable stents, contributing 18% of regional advanced biomaterial demand. 

• Middle East & Africa

The Middle East & Africa represented 6% of the global bioresorbable medical material market in 2025. Saudi Arabia and the United Arab Emirates together contributed 48% of regional demand due to expanding healthcare infrastructure and orthopedic treatment capabilities. Orthopedic applications represented 37% of regional biomaterial utilization because of rising trauma surgery procedures and sports injury treatments.

Biodegradable wound healing materials accounted for 22% of regional demand, particularly across advanced hospital facilities and specialty clinics. More than 430 healthcare facilities across the Middle East adopted absorbable implant systems during 2025. Polymer-based biomaterials represented 64% of total product utilization because of increasing preference for minimally invasive treatments. South Africa contributed 19% of regional market demand due to expanding regenerative medicine and surgical implant adoption. 

List of Top Bioresorbable Medical Material Companies

• Evonik
• Corbion
• DSM
• Mitsui Chemicals
• PCAS
• Poly-Med
• KLS Martin

Top Two Companies with Highest Market Share

• Evonik held approximately 27% share of global bioresorbable medical material supply in 2025 due to strong pharmaceutical polymer production and advanced biomaterial research capabilities.

• Corbion accounted for nearly 18% market share globally because of extensive PLA biomaterial manufacturing capacity and strong biodegradable polymer innovation activities.

Investment Analysis and Opportunities

Investments in the bioresorbable medical material market increased significantly during 2025 due to expanding regenerative medicine research, orthopedic implant demand, and advanced drug delivery development. More than 44% of biomaterial manufacturers increased investments in biodegradable polymer synthesis technologies and tissue engineering research platforms. Drug delivery applications represented 39% of total investment activity globally because of rising demand for controlled-release therapeutics.

Orthopedic biomaterial production facilities expanded manufacturing capacity by 23% between 2023 and 2025 to support increasing absorbable implant demand. More than 540 clinical research projects worldwide focused on biodegradable scaffold technologies and regenerative medicine applications during 2025. Polymer-based biomaterials represented 72% of total investment allocation because of strong clinical adoption and broad application compatibility.

New Product Development

New product development in the bioresorbable medical material market accelerated rapidly during 2025 due to advancements in polymer science, nanotechnology, and regenerative medicine. More than 24% of newly developed biomaterial products focused on controlled degradation systems for orthopedic and cardiovascular implants. PLA and PLGA materials represented 57% of newly launched biodegradable medical products because of high biocompatibility and predictable resorption characteristics. 3D-printed biodegradable scaffolds accounted for 22% of new regenerative medicine developments during 2025.

Nanotechnology-enhanced biomaterials improved tissue regeneration efficiency by 31% and increased cellular adhesion performance across advanced implant applications. Smart biodegradable implants with antimicrobial coatings represented 19% of newly introduced orthopedic and wound healing products. Drug delivery innovations remained a major focus area, with controlled-release microsphere technologies reducing dosing frequency by 42% in chronic disease management applications. 

Five Recent Developments (2023-2025)

• In 2025, Evonik expanded biodegradable polymer production capacity by 21% to support increasing pharmaceutical drug delivery and orthopedic implant demand.
• In 2024, Corbion introduced advanced PLA biomaterials with 18% higher mechanical stability for absorbable orthopedic fixation systems.
• In 2025, DSM developed nanotechnology-integrated biodegradable polymers improving tissue regeneration efficiency by 31% in regenerative medicine applications.
• In 2023, Mitsui Chemicals launched high-purity PLGA materials for controlled-release pharmaceutical systems reducing dosing frequency by 37%.
• In 2024, Poly-Med introduced 3D-printable bioresorbable scaffold materials improving implant customization accuracy by 26% for tissue engineering applications.

Report Coverage of Bioresorbable Medical Material Market

The bioresorbable medical material market report provides comprehensive analysis of biodegradable polymer technologies, medical applications, regional demand patterns, competitive manufacturing activities, and technological advancements across global healthcare sectors. The study evaluates more than 55 biomaterial manufacturers involved in orthopedic implants, drug delivery systems, tissue engineering, and regenerative medicine applications. Polymer-based biomaterials accounted for 72% of analyzed medical product utilization due to superior biodegradation and biocompatibility characteristics.

The report covers segmentation by material type including polylactic acid, polyglycolic acid, polysaccharides, polycaprolactone, and PLGA. Drug delivery applications represented 39% of analyzed demand, while orthopedic procedures accounted for 28% of global product utilization during 2025. More than 11 million biodegradable implant procedures were assessed within the study scope.